The companies will jointly validate novel drug targets identified by Scipher's molecular interaction network platform for patients with inflammatory bowel disease.
The startup aims to develop a low-cost, high-throughput proteomics platform that combines biochemistry with computer science and information technology.
The company believes it can provide tests to predict patients' responsiveness to specific drugs akin to the molecular diagnostics that have now swelled the oncology space.
Using pathway and network analyses, researchers identified overlapping genes and biological processes behind smoking and schizophrenia, including new candidate genes.
The Danish informatics firm is exploring analytical tools for its InWeb_InBioMap network, which currently contains more than 700,000 protein-protein interactions.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
